On October 1, 2021 Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, reported a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, to be held in Washington, D.C. and in a virtual platform on November 10-14, 2021 (Press release, Aleta Biotherapeutics, OCT 1, 2021, View Source [SID1234590664]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full details of the poster presentation are listed below:

Title: Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors
Presenter: Paul D. Rennert, PhD
Date & Time: Available 7 a.m. EST on Friday, November 12, 2021
Poster Session: Cellular Therapies
Abstract Number: 160